As Synergy Pharmaceuticals Del (SGYP) Stock Price Declined, Great Point Partners LLC Trimmed Its Stake

March 14, 2018 - By Marguerite Chambers

Investors sentiment increased to 1.9 in 2017 Q3. Its up 0.41, from 1.49 in 2017Q2. It increased, as 16 investors sold SGYP shares while 23 reduced holdings. 21 funds opened positions while 53 raised stakes. 147.06 million shares or 7.33% less from 158.68 million shares in 2017Q2 were reported. Citadel Advsr Lc reported 0.01% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). State Board Of Administration Of Florida Retirement System accumulated 80,256 shares or 0% of the stock. Bancorp Of America Corporation De holds 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) or 88,245 shares. Voya Lc holds 0% or 104,372 shares in its portfolio. Royal Comml Bank Of Canada owns 27,595 shares for 0% of their portfolio. Susquehanna Int Grp Limited Liability Partnership stated it has 2.53 million shares or 0% of all its holdings. Virtu Financial Ltd Liability Corp has invested 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Ameritas Invest Partners Inc stated it has 19,906 shares. 20,600 were reported by Quantitative Investment Mgmt Lc. Equitec Specialists Ltd holds 0% or 3,000 shares. Deutsche Bancorporation Ag accumulated 2.38M shares. Moreover, Tiaa Cref Llc has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 1.23 million shares. First Advsrs LP holds 13,210 shares or 0% of its portfolio. Ing Groep Nv holds 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 17,500 shares. New York-based Family Mngmt has invested 0.16% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP).

Jeffrey Jay decreased its stake in Synergy Pharmaceuticals Del (SGYP) by 54.68% based on its latest 2017Q3 regulatory filing with the SEC. Great Point Partners Llc sold 3.95M shares as the company’s stock declined 35.42% while stock markets rallied. The hedge fund run by Jeffrey Jay held 3.27 million shares of the health care company at the end of 2017Q3, valued at $9.49M, down from 7.22M at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Synergy Pharmaceuticals Del for a number of months, seems to be less bullish one the $515.52M market cap company. The stock decreased 0.48% or $0.01 during the last trading session, reaching $2.09. About 1.76 million shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since March 14, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

Analysts await Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report earnings on May, 9. They expect $-0.16 EPS, up 46.67 % or $0.14 from last year’s $-0.3 per share. After $-0.18 actual EPS reported by Synergy Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -11.11 % EPS growth.

More notable recent Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) news were published by: which released: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Synergy …” on February 21, 2018, also with their article: “Synergy Pharmaceuticals’ Cash Flow And Prescription Trends” published on March 08, 2018, published: “Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.” on February 24, 2018. More interesting news about Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) were released by: and their article: “Synergy Pharmaceuticals: Things Are Looking Better” published on March 05, 2018 as well as‘s news article titled: “Synergy Pharmaceuticals: Q4 Earnings Highlights” with publication date: March 02, 2018.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Ratings Coverage

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 42 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, September 25. The firm has “Buy” rating by H.C. Wainwright given on Monday, March 5. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, November 21 report. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by BTIG Research on Tuesday, August 25. The firm has “Outperform” rating given on Thursday, January 5 by Oppenheimer. Citigroup maintained the shares of SGYP in report on Wednesday, March 16 with “Neutral” rating. Cantor Fitzgerald initiated it with “Buy” rating and $1100 target in Thursday, June 1 report. Canaccord Genuity maintained the shares of SGYP in report on Friday, November 10 with “Buy” rating. The firm has “” rating by Roth Capital given on Thursday, October 29. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, September 27.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.